MY136635A - Treatment of patients having non-hodgkins lymphoma with bone marrow involvement with anti-cd20 antibodies - Google Patents

Treatment of patients having non-hodgkins lymphoma with bone marrow involvement with anti-cd20 antibodies

Info

Publication number
MY136635A
MY136635A MYPI20003551A MYPI20003551A MY136635A MY 136635 A MY136635 A MY 136635A MY PI20003551 A MYPI20003551 A MY PI20003551A MY PI20003551 A MYPI20003551 A MY PI20003551A MY 136635 A MY136635 A MY 136635A
Authority
MY
Malaysia
Prior art keywords
bone marrow
antibodies
patients
treatment
marrow involvement
Prior art date
Application number
MYPI20003551A
Other languages
English (en)
Inventor
William H Rastetter
Original Assignee
Biogen Idec Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen Idec Inc filed Critical Biogen Idec Inc
Publication of MY136635A publication Critical patent/MY136635A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MYPI20003551A 1999-08-11 2000-08-03 Treatment of patients having non-hodgkins lymphoma with bone marrow involvement with anti-cd20 antibodies MY136635A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US14828799P 1999-08-11 1999-08-11

Publications (1)

Publication Number Publication Date
MY136635A true MY136635A (en) 2008-11-28

Family

ID=22525101

Family Applications (1)

Application Number Title Priority Date Filing Date
MYPI20003551A MY136635A (en) 1999-08-11 2000-08-03 Treatment of patients having non-hodgkins lymphoma with bone marrow involvement with anti-cd20 antibodies

Country Status (11)

Country Link
EP (1) EP1207906A4 (zh)
JP (1) JP2003513012A (zh)
CN (2) CN101259270A (zh)
AU (1) AU784971B2 (zh)
CA (1) CA2378646A1 (zh)
HK (1) HK1048945A1 (zh)
MX (1) MXPA02001398A (zh)
MY (1) MY136635A (zh)
NO (1) NO20020639L (zh)
TW (1) TWI279233B (zh)
WO (1) WO2001010462A1 (zh)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN100358577C (zh) 1999-05-07 2008-01-02 杰南技术公司 抗体在制备治疗哺乳动物自身免疫病的试剂中的用途
US7754208B2 (en) 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
US20030133939A1 (en) 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
KR100932340B1 (ko) 2002-10-17 2009-12-16 젠맵 에이/에스 Ｃｄ20에 대한 인간 모노클로날 항체
EP3263596A1 (en) 2002-12-16 2018-01-03 Genentech, Inc. Immunoglobulin variants and uses thereof
ZA200507805B (en) 2003-04-09 2006-12-27 Genentech Inc Therapy of autoimmune disease in a patient with an inadequate response to a TNF-alpha inhibitor
NZ568403A (en) 2003-05-09 2009-10-30 Univ Duke CD20-specific antibodies and methods of employing same
JP2007526220A (ja) 2003-06-05 2007-09-13 ジェネンテック・インコーポレーテッド Ｂ細胞疾患の併用療法
EA025962B1 (ru) 2003-11-05 2017-02-28 Роше Гликарт Аг АНТИТЕЛА, ОБЛАДАЮЩИЕ ПОВЫШЕННОЙ АФФИННОСТЬЮ К СВЯЗЫВАНИЮ С Fc-РЕЦЕПТОРОМ И ЭФФЕКТОРНОЙ ФУНКЦИЕЙ
JP5848861B2 (ja) 2004-04-20 2016-01-27 ジェンマブ エー／エスＧｅｎｍａｂ Ａ／Ｓ Ｃｄ２０に対するヒトモノクローナル抗体
TW201422238A (zh) 2004-06-04 2014-06-16 Genentech Inc Ｃｄ２０抗體於治療多發性硬化症之用途及用於該用途之物品
PL1776384T3 (pl) 2004-08-04 2013-10-31 Mentrik Biotech Llc WARIANTY REGIONÓW Fc
EP1919505A2 (en) 2005-07-25 2008-05-14 Trubion Pharmaceuticals, Inc. Single dose use of cd20-specific binding molecules
DK2298815T3 (en) 2005-07-25 2015-06-15 Emergent Product Dev Seattle B-CELL REDUCTION USING CD37 SPECIFIC AND CD20 SPECIFIC BINDING MOLECULES
MY149159A (en) 2005-11-15 2013-07-31 Hoffmann La Roche Method for treating joint damage
US9726673B2 (en) 2005-11-23 2017-08-08 Genentech, Inc. Methods and compositions related to B cell assays
CA2654317A1 (en) 2006-06-12 2007-12-21 Trubion Pharmaceuticals, Inc. Single-chain multivalent binding proteins with effector function
CA3113365A1 (en) 2007-07-09 2009-01-15 Genentech, Inc. Prevention of disulfide bond reduction during recombinant production of polypeptides
DK2233149T3 (en) 2007-10-16 2016-05-17 Zymogenetics Inc COMBINATION OF TRANSMEMBRANAKTIVATOR AND CALCIUM MODULATOR AND cyclophilin-LIGAND INTERAKTOR (TACI) AND ANTI-CD20 MEANS FOR TREATMENT OF AUTO-IMMUNE DISEASE
EP2077281A1 (en) 2008-01-02 2009-07-08 Bergen Teknologioverforing AS Anti-CD20 antibodies or fragments thereof for the treatment of chronic fatigue syndrome
US7914785B2 (en) 2008-01-02 2011-03-29 Bergen Teknologieverforing As B-cell depleting agents, like anti-CD20 antibodies or fragments thereof for the treatment of chronic fatigue syndrome
NZ621443A (en) 2008-04-11 2015-09-25 Emergent Product Dev Seattle Cd37 immunotherapeutic and combination with bifunctional chemotherapeutic thereof
TW201438738A (zh) 2008-09-16 2014-10-16 Genentech Inc 治療進展型多發性硬化症之方法
WO2010075249A2 (en) 2008-12-22 2010-07-01 Genentech, Inc. A method for treating rheumatoid arthritis with b-cell antagonists
CN102264368B (zh) * 2008-12-22 2014-09-10 米伦纽姆医药公司 极光激酶抑制剂与抗cd20抗体的组合
JO3434B1 (ar) 2009-07-31 2019-10-20 Millennium Pharm Inc مركبات صيدلانية لمعالجة السرطان وامراض واضطرابات اخري
US8512983B2 (en) 2009-08-11 2013-08-20 Martin Gawlitzek Production of proteins in glutamine-free cell culture media
AR080154A1 (es) 2010-02-10 2012-03-14 Immunogen Inc Anticuerpos cd20 y su utilizacion
CA2788774A1 (en) 2010-02-19 2011-08-25 Millennium Pharmaceuticals, Inc. Crystalline forms of sodium 4-{[9-chloro-7-(2-fluoro-6-methoxyphenyl)-5h-pyrimido[5,4-d][2]benzazepin-2-yl]amino}-2-methoxybenzoate
US9814740B2 (en) * 2010-12-21 2017-11-14 Duke University Methods and compositions combining immunotherapy with monocyte activation
US10017739B2 (en) 2012-09-06 2018-07-10 Duke University Methods of expanding and assessing B cells and using expanded B cells to treat disease
US9724354B2 (en) 2013-03-22 2017-08-08 Millennium Pharmaceuticals, Inc. Combination of catalytic mTORC1/2 inhibitors and selective inhibitors of Aurora A kinase
WO2016118353A1 (en) * 2015-01-23 2016-07-28 Immunomedics, Inc. Combination therapy with anti-cd74 and anti-cd20 antibodies in patients with relapsed and refractory b-cell non-hodgkin's lymphoma
SI3303373T1 (sl) 2015-05-30 2020-07-31 Molecular Templates, Inc. Deimunizirana ogrodja A podenot Shiga toksina in celice-ciljajoče molekule, ki jih obsegajo
ES2908009T3 (es) 2015-06-24 2022-04-27 Hoffmann La Roche Anticuerpos anti-receptor de transferrina con afinidad adaptada
US11352426B2 (en) 2015-09-21 2022-06-07 Aptevo Research And Development Llc CD3 binding polypeptides
AR106189A1 (es) 2015-10-02 2017-12-20 Hoffmann La Roche ANTICUERPOS BIESPECÍFICOS CONTRA EL A-b HUMANO Y EL RECEPTOR DE TRANSFERRINA HUMANO Y MÉTODOS DE USO
MA43023A (fr) 2015-10-02 2018-08-08 Hoffmann La Roche Anticorps de récepteur de la transferrine humaine/anti-humaine cd20 bispécifique et leurs procédés d'utilisation
MX2019003029A (es) * 2016-09-16 2019-09-13 Nordic Nanovector Asa Tratamiento de linfoma no hodgkin usando lilotomab y 177lu-lilotomab satetraxetano.
CN108421048B (zh) * 2016-09-28 2021-04-20 首都医科大学附属北京世纪坛医院 纳米活性碳靶向药物递送***、制备方法及其用途

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE196606T1 (de) * 1992-11-13 2000-10-15 Idec Pharma Corp Therapeutische verwendung von chimerischen und markierten antikörpern, die gegen ein differenzierung-antigen gerichtet sind, dessen expression auf menschliche b lymphozyt beschränkt ist, für die behandlung von b-zell-lymphoma
US5595721A (en) * 1993-09-16 1997-01-21 Coulter Pharmaceutical, Inc. Radioimmunotherapy of lymphoma using anti-CD20
CA2340091C (en) * 1998-08-11 2013-02-05 Idec Pharmaceuticals Corporation Combination therapies for b-cell lymphomas comprising administration of anti-cd20 antibody
US8557244B1 (en) * 1999-08-11 2013-10-15 Biogen Idec Inc. Treatment of aggressive non-Hodgkins lymphoma with anti-CD20 antibody
US6451284B1 (en) * 1999-08-11 2002-09-17 Idec Pharmaceuticals Corporation Clinical parameters for determining hematologic toxicity prior to radioimmunotheraphy

Also Published As

Publication number Publication date
NO20020639D0 (no) 2002-02-08
NO20020639L (no) 2002-04-11
CN1373671A (zh) 2002-10-09
AU784971B2 (en) 2006-08-10
EP1207906A1 (en) 2002-05-29
EP1207906A4 (en) 2005-07-06
TWI279233B (en) 2007-04-21
WO2001010462A1 (en) 2001-02-15
MXPA02001398A (es) 2002-08-12
HK1048945A1 (en) 2003-04-25
CA2378646A1 (en) 2001-02-15
CN101259270A (zh) 2008-09-10
JP2003513012A (ja) 2003-04-08
CN100389825C (zh) 2008-05-28
AU7626000A (en) 2001-03-05

Similar Documents

Publication Publication Date Title
MY136635A (en) Treatment of patients having non-hodgkins lymphoma with bone marrow involvement with anti-cd20 antibodies
AU2003205077A1 (en) Imaging agents and methods of imaging naaladase of psma
CY1110681T1 (el) Θεραπεια me anti-cd20 αντισωμα ασθενων που λαμβανουν μοσχευματα βμτ ή pbsc
MY136203A (en) Combination therapies for b-cell lymphomas comprising administration of anti-cd20 antibody
RS20050802A (en) Combinations for the treatment of diseases involving cell proliferation,migration or apoptosis of myeloma cells,or angiogeneis
TW200612918A (en) Lonidamine analogs
PT1207904E (pt) Novos parâmetros clínicos para a determinação de toxicidade hematológica prévia à radioimunoterapia
IL169896A0 (en) Methods and compositions for administering therapeutic and diagnostic agents
UA89350C2 (uk) Гуманізоване антитіло, що зв'язує людський cd20
WO2006029219A3 (en) Human monoclonal anti-ctla4 antibodies in cancer treatment
MY151032A (en) Treatment of tnf? related disorders
DE60028970D1 (de) An her2 bindende peptidverbindungen
UA84954C2 (ru) Конденсированные пиримидоны, пригодные для лечения и профилактики злокачественного новообразования
MXPA04003674A (es) Uso mejorado de compuesto antitumoral en terapia de cancer.
EA200600921A1 (ru) Способы и композиции с применением талидомида для лечения и менеджмента рака и других заболеваний
IL146125A0 (en) Novel quinones as disease therapies
MX2009010269A (es) Metodos de tratamiento del cancer mediante administracion de combinaciones de interleucina-18 humana.
AP2003002785A0 (en) Treatment of t cell disorders
AU2003216109A1 (en) Therapeutic composition for treatment of cancer by arginine depletion
WO2007109648A3 (en) Compositions and methods for modulating store-operated calcium entry
MXPA05010575A (es) Peptacuerpo para el tratamiento del cancer.
WO2005058251A3 (en) Hla-dr-specific antibodies, compositions and methods
DK1185279T3 (da) Midler til behandling af maligne sygdomme ved anvendelse af proteinet YB-1
MXPA02011563A (es) Composicionesy metodos para la terapia y diagnostico de cancer de seno.
AU2001233912A1 (en) Diagnosis of breast cancer using bcmp-81 as marker